Stock Track | YIDU TECH Soars 5.57% After Winning Bid for Eye Drop Clinical Research Project

Stock Track

Sep 24

YIDU TECH (02158) shares are soaring in intraday trading, with the stock price surging 5.57% to HK$6.06. The company's stock has seen active trading, with a turnover reaching HK$74.9734 million as of the latest update.

The significant uptick in YIDU TECH's stock price comes on the heels of a major announcement. The company revealed that its affiliated entity, Tianjin Happy Life Technology Co., Ltd., has successfully won the bid for a crucial clinical research project. The project involves Phase III clinical research for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drop. The total value of this project is approximately RMB 55.82 million, marking a substantial business opportunity for YIDU TECH.

YIDU TECH, known as China's AI medical transformation driver, has positioned itself at the forefront of healthcare innovation. The company has developed a "data-algorithm-scenario" flywheel closed loop based on its proprietary core algorithm engine, YiduCore. This technology enables high-efficiency innovation and low-cost scaled application of AI technology, driving intelligent decision-making across the entire "medical-pharmaceutical-insurance-patient" ecosystem. The recent project win further solidifies YIDU TECH's role in advancing medical research and development in China's healthcare sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1111165868"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111165868\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111165868?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-24 11:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111165868","market":"sg","top_or_hot":-1,"title":"Stock Track | YIDU TECH Soars 5.57% After Winning Bid for Eye Drop Clinical Research Project","media":"Stock Track","content":"<p>YIDU TECH (02158) shares are soaring in intraday trading, with the stock price surging 5.57% to HK$6.06. The company's stock has seen active trading, with a turnover reaching HK$74.9734 million as of the latest update.</p>\n\n<p>The significant uptick in YIDU TECH's stock price comes on the heels of a major announcement. The company revealed that its affiliated entity, Tianjin Happy Life Technology Co., Ltd., has successfully won the bid for a crucial clinical research project. The project involves Phase III clinical research for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drop. The total value of this project is approximately RMB 55.82 million, marking a substantial business opportunity for YIDU TECH.</p>\n\n<p>YIDU TECH, known as China's AI medical transformation driver, has positioned itself at the forefront of healthcare innovation. The company has developed a \"data-algorithm-scenario\" flywheel closed loop based on its proprietary core algorithm engine, YiduCore. This technology enables high-efficiency innovation and low-cost scaled application of AI technology, driving intelligent decision-making across the entire \"medical-pharmaceutical-insurance-patient\" ecosystem. The recent project win further solidifies YIDU TECH's role in advancing medical research and development in China's healthcare sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | YIDU TECH Soars 5.57% After Winning Bid for Eye Drop Clinical Research Project</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | YIDU TECH Soars 5.57% After Winning Bid for Eye Drop Clinical Research Project\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-09-24 11:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>YIDU TECH (02158) shares are soaring in intraday trading, with the stock price surging 5.57% to HK$6.06. The company's stock has seen active trading, with a turnover reaching HK$74.9734 million as of the latest update.</p>\n\n<p>The significant uptick in YIDU TECH's stock price comes on the heels of a major announcement. The company revealed that its affiliated entity, Tianjin Happy Life Technology Co., Ltd., has successfully won the bid for a crucial clinical research project. The project involves Phase III clinical research for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drop. The total value of this project is approximately RMB 55.82 million, marking a substantial business opportunity for YIDU TECH.</p>\n\n<p>YIDU TECH, known as China's AI medical transformation driver, has positioned itself at the forefront of healthcare innovation. The company has developed a \"data-algorithm-scenario\" flywheel closed loop based on its proprietary core algorithm engine, YiduCore. This technology enables high-efficiency innovation and low-cost scaled application of AI technology, driving intelligent decision-making across the entire \"medical-pharmaceutical-insurance-patient\" ecosystem. The recent project win further solidifies YIDU TECH's role in advancing medical research and development in China's healthcare sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02158","symbol_name":"医渡科技","start_time":0,"source_url":"","article_id":"1111165868","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111165868","pubTimestamp":1758685474,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"YIDU TECH (02158) shares are soaring in intraday trading, with the stock price surging 5.57% to HK$6.06. The company's stock has seen active trading, with a turnover reaching HK$74.9734 million as of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02158":"医渡科技"},"translate_title":"个股赛道|中标滴眼液临床研究项目医渡科技大涨5.57%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02158":1},"content_text":"YIDU TECH (02158) shares are soaring in intraday trading, with the stock price surging 5.57% to HK$6.06. The company's stock has seen active trading, with a turnover reaching HK$74.9734 million as of the latest update.\nThe significant uptick in YIDU TECH's stock price comes on the heels of a major announcement. The company revealed that its affiliated entity, Tianjin Happy Life Technology Co., Ltd., has successfully won the bid for a crucial clinical research project. The project involves Phase III clinical research for Shandong Yandu Biotechnology Co., Ltd.'s recombinant human nerve growth factor (SMR001) eye drop. The total value of this project is approximately RMB 55.82 million, marking a substantial business opportunity for YIDU TECH.\nYIDU TECH, known as China's AI medical transformation driver, has positioned itself at the forefront of healthcare innovation. The company has developed a \"data-algorithm-scenario\" flywheel closed loop based on its proprietary core algorithm engine, YiduCore. This technology enables high-efficiency innovation and low-cost scaled application of AI technology, driving intelligent decision-making across the entire \"medical-pharmaceutical-insurance-patient\" ecosystem. The recent project win further solidifies YIDU TECH's role in advancing medical research and development in China's healthcare sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}